Skip to main content

Animations

MJFF Publications

6501 - 6510 of 8571 Results
Title
Year
  • Year
  • 2010
  • 2012
  • 2012
  • 2009
  • 2011
  • 2010
  • 2009
  • 2019
  • 2013
  • 2016
  • Summary Details
    OPEN
    Title: Lentiviral Overexpression of GRK6 Alleviates l -Dopa–Induced Dyskinesia in Experimental Parkinson’s Disease
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.3000664
    Citation Count: 135
  • Summary Details
    OPEN
    Title: Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease
    Journal Name: Science Translational Medicine
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1126/scitranslmed.3003985
    Citation Count: 484
  • Summary Details
    OPEN
    Title: Pantothenate kinase‐associated neurodegeneration is not a synucleinopathy
    Journal Name: Neuropathology and Applied Neurobiology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: unspecified-oa
    DOI - Digital Object Identifier: 10.1111/j.1365-2990.2012.01269.x
    Citation Count: 52
  • Summary Details
    OPEN
    Title: Evaluation of the D3 dopamine receptor selective antagonist PG01037 on l-dopa-dependent abnormal involuntary movements in rats
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2009.01.020
    Citation Count: 46
  • Summary Details
    OPEN
    Title: Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2010.12.032
    Citation Count: 71
  • Summary Details
    OPEN
    Title: Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on l-dopa dependent animal involuntary movements in rats
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2010.09.011
    Citation Count: 20
  • Summary Details
    OPEN
    Title: Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2009.01.019
    Citation Count: 53
  • Summary Details
    OPEN
    Title: The misallocation of climate research funding
    Journal Name: Energy Research & Social Science
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.erss.2019.101349
    Citation Count: 248
  • Summary Details
    OPEN
    Title: Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder
    Journal Name: Sleep Medicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.sleep.2012.10.015
    Citation Count: 370
  • Summary Details
    OPEN
    Title: Assessing medication role on neuropathological findings in Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.26536
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.